Subscribe Become an Author Log In

Decisions supported by knowledge

Contributor Biopharma Insights

David Shlaes

Dr. Shlaes, author of Antibiotics, The Perfect Storm (Springer) and The Drug Makers (Lulu), has had a thirty year career in anti-infectives spanning academia and industry with a long-standing scientific interest in antimicrobial resistance. He trained in infectious diseases at Case Western Reserve University in Cleveland. He then joined the faculty and ultimately became a Professor of Medicine there. Dr. Shlaes left academia to become Vice President for Infectious Diseases at Wyeth Pharmaceuticals in 1996. There he was an important leader in the development of tigecycline. In 1998, he was the cover feature in the April issue of Business Week dedicated to antibiotics research. He also was a member of the Forum for Emerging Infections of the National Academy of Sciences for seven years. In 2002, Dr. Shlaes became Executive Vice President, Research and Development for Idenix, Pharmaceuticals, a company located in Cambridge, MA focused on the discovery and development of antivirals. In 2005, he established a consulting company. During his consulting years he contributed in significant ways to the development of avibactam, eravacycline and lefamulin. During his working career, he lived in Paris, France for several years. Dr. Shlaes has since retired from Anti-infectives Consulting. He remains an Editor for Antimicrobial Agents and Chemotherapy, writes a blog – Antibiotics the Perfect Storm – and he continues to be active in antibiotic policy areas.


Antibiotics Pharmaceutical industry trends Thought-provoking

Posts by this author

Will 2019 Bring Positive Signals for the Declining Antibiotics R&D Market?

Will 2019 Bring Positive Signals for the Declining Antibiotics R&D Market?

Antibiotic R&D has had a particularly bad year starting with The Medicines Company who abandoned their antibiotic R&D efforts and sold their antibiotic assets to Melinta late last year right after getting approval for vabomere. This year both Sanofi and Novartis abandoned their antibiotic R&D efforts and divested their clinical and preclinical assets. Allergan, holder of the North American rights to ceftaroline, dalbavancin and ceftazidime-avibactam, also announced that they would divest their antibiotic assets. I have not heard that they were successful. Achaogen has now undergone two efforts at “restructuring” involving virtually eliminating all R&D and has essentially put up the “for sale” sign just after achieving approval for plazomicin. Finally, Melinta abandoned their antibiotic R&D efforts in the face of miserable sales of their recently launched antibiotics including delafloxacin and vabomere.